枸缘酸乙胺嗪(Diethylcarbamazine Citrate) - 药物靶点：COX-1_在研适应症：丝虫病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Diethylcarbamazine、Diethylcarbamazine citrate (JP17/USP)

+ [5]

靶点

COX-1

作用机制

COX-1抑制剂(环氧化酶-1抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Mitsubishi Tanabe Pharma Corp.

非在研机构

Lederle Cyanamid Canada Inc

Lederle Laboratories

最高研发阶段批准上市

首次获批日期

美国 (1950-11-13),

丝虫性象皮病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C16H29N3O8

InChIKeyPGNKBEARDDELNB-UHFFFAOYSA-N

CAS号1642-54-2

查看全部结构式(2)

关联

18

项与枸缘酸乙胺嗪相关的临床试验

CTRI/2022/11/047741 / Not yet recruitingN/AIIT

A comparative study on the efficacy of diethylcarbamazine as an adjuvant therapy with standard therapy in the treatment of allergic rhinitis

开始日期2022-12-01

申办/合作机构-

NCT04410406 / Active, not recruiting临床3期IIT

A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis

The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).

开始日期2020-08-20

申办/合作机构

Washington University School of Medicine

[+1]

CTRI/2020/03/024145 / Not yet recruitingN/A

Efficacy and safety of diethyl carbamazine in treatment of allergic rhinitis: a double blind randomised controlled trial

开始日期2020-03-23

申办/合作机构-

100 项与枸缘酸乙胺嗪相关的临床结果

登录后查看更多信息

100 项与枸缘酸乙胺嗪相关的转化医学

登录后查看更多信息

100 项与枸缘酸乙胺嗪相关的专利（医药）

登录后查看更多信息

1,862

项与枸缘酸乙胺嗪相关的文献（医药）

2024-12-01·Molecular Biology Reports

Detection of Wuchereria bancrofti DNA in wild caught vector and non-vector mosquitoes: implications for elimination of lymphatic filariasis

Article

作者: Hoti, Sugeerappa Laxmanappa ; Adinarayanan, Srividya ; Kumar, Ashwani ; Raju, Konuganti Hari Kishan ; Venkatesan, Vasuki ; Ramalingam, Balasubramaniyan ; Swaminathan, Subramanian ; Abraham, Philip Raj

BACKGROUNDTransmission Assessment Survey (TAS) is the WHO recommended method used for decision-making to stop or continue the MDA in lymphatic filariasis (LF) elimination programme. The WHO has also recommended Molecular Xenomonitoring (MX) of LF infection in vectors as an adjunct tool in settings under post-MDA or validation period. Screening of non-vectors by MX in post-MDA / validation settings could be useful to prevent a resurgence of LF infection, as there might be low abundance of vectors, especially in some seasons. In this study, we investigated the presence of LF infection in non-vectors in an area endemic for LF and has undergone many rounds of annual MDA with two drugs (Diethylcarbamazine and Albendazole, DA) and two rounds of triple drug regimens (Ivermectin + DA).METHODS AND RESULTSMosquitoes were collected from selected villages of Yadgir district in Karnataka state, India, during 2019. A total of 680 female mosquitoes were collected, identified morphologically by species and separated as pools. The female mosquitoes belonging to 3 species viz., Anopheles subpictus, Culex gelidus and Culex quinquefaciatus were separated, pooled, and the DNA extracted using less expensive method and followed by LDR based real-time PCR assay for detecting Wuchereria bancrofti infection in vector as well as non-vector mosquitoes. One pool out of 6 pools of An. subpictus, 2 pools out of 6 pools of Cx. gelidus, and 4 pools out of 8 pools of Cx. quinquefaciatus were found to be positive for W. bancrofti infection by RT-PCR. The infection rate in vectors and non-vectors was found to be 1.8% (95% CI: 0.5-4.2%) and 0.9% (95% CI: 0.2-2.3%), respectively.CONCLUSIONSOur study showed that non-vectors also harbour W. bancrofti, thus opening an opportunity of using these mosquitoes as surrogate vectors for assessing risk of transmission to humans in LF endemic and post MDA areas.

2024-11-01·Current Topics in Medicinal Chemistry

An Overview on Antifilarial Efficacy of Heterocyclic Motifs Encompassing Synthetic Strategies, SAR, and Commercialized Medications

Article

作者: Tahlan, Sumit ; Pandey, Kailash C ; Singh, Sucheta

Abstract:Filariasis is one of the oldest, most dangerous, debilitating, disfiguring diseases and often ignores tropical disorders. It presents with a range of clinical symptoms, a low death rate, and a high morbidity rate, which contributes to social discrimination. This condition has major effects on people's socioeconomic circumstances. This illness is carried by mosquitoes that have spread malaria. Lymphatic filariasis, caused by Wuchereria bancrofti, Brugia malayi, and Brugia timori, is a crippling illness with serious social and economic consequences. The infection persisted despite therapy with conventional antifilarial medications such as diethylcarbamazine (DEC), albendazole, and ivermectin, which are mostly microfilaricides. Current treatments (ivermectin, diethylcarbamazine, and albendazole) have limited effectiveness against adult parasites and produce side effects; therefore, innovative antifilarial medications are urgently required. Hence, macrofilaricides, embryostatic agents, and improved microfilaricides are required. The following article discusses the typical synthetic methodologies established for antifilarial activity as well as their marketed pharmaceuticals, which will help researchers, medicinal chemists, and pharmaceutical scientists to develop new and effective antifilarial therapies. This review can help to identify new lead compounds and optimize existing commercial medications to improve their therapeutic efficacy. The majority of the studies addressed in this review concern the forms of filariasis, parasite life cycle, symptoms, medications used to treat filariasis, synthetic schemes, SAR, and results from the reported research.

2024-09-04·The American Journal of Tropical Medicine and Hygiene

Imported Loiasis at a Clinical Reference Center in Germany: A Retrospective Case Series

Article

作者: Ramharter, Michael ; Ruge, Julia ; Tappe, Dennis ; Nordmann, Tamara

ABSTRACT.Loiasis is a rarely imported infectious disease that is often difficult to diagnose and treat. Here we describe clinical features and treatment outcomes of 11 patients with imported loiasis seen at a German reference center between 2013 and 2023. Clinical presentations varied by patient origin, with eye-worm migration and ophthalmological symptoms being more common among patients from endemic areas and Calabar swelling, subcutaneous swelling, and pruritus more prevalent among returning travelers from nonendemic regions. Eosinophil counts were higher in returning travelers. Diethylcarbamazine was most commonly used for treatment either as monotherapy in combination with ivermectin or with albendazole and ivermectin, respectively. In one patient, long-term follow-up indicated treatment failure after the first course of treatment. Another traveler was prescribed chemoprophylaxis with diethylcarbamazine after experiencing repeated infections due to long-term residence in a high-risk region in Cameroon.

100 项与枸缘酸乙胺嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00803	枸缘酸乙胺嗪	P02CB02	DB00711

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
丝虫病	日本	Mitsubishi Tanabe Pharma Corp.	1951-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	临床3期	丝虫性象皮病 Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	(淵衊鬱鬱壓獵襯製廠廠) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) 鬱鏇鹹鏇膚壓製繭鑰艱 (選網蓋醖壓襯夢餘願醖 ) 更多	积极	2023-09-18
				moxidectin + albendazole
NCT04188301 (DOLF IDA/Oncho, CTgov)	临床2期	盘尾丝虫病	154	Albendazole+Ivermectin (IVM + ALB)	顧壓範憲鬱廠餘夢蓋餘(鏇顧鬱構鬱簾鹽衊鏇構) = 繭蓋憲鏇構窪窪淵蓋築觸顧醖夢積簾積廠網積 (蓋襯鹹醖鬱衊鬱顧艱夢, 糧鬱艱簾鏇顧淵淵鬱選 ~ 構壓觸壓壓觸窪製襯觸) 更多	-	2023-05-10
				albendazole+ivermectin+diethylcarbamazine (IDA x 1 Dose)	顧壓範憲鬱廠餘夢蓋餘(鏇顧鬱構鬱簾鹽衊鏇構) = 製獵襯簾構繭壓鏇蓋襯觸顧醖夢積簾積廠網積 (蓋襯鹹醖鬱衊鬱顧艱夢, 繭網積構鹹廠簾築膚憲 ~ 簾糧憲壓憲鹽願衊醖選) 更多
ATS2022	N/A	嗜酸粒细胞增多症	-	Diethylcarbamazine	廠蓋廠鑰襯選築艱願醖(選選範齋醖糧築蓋夢簾) = The patient continued to experience wheezes despite two rounds of DEC. A trial of ivermectin was initiated in addition to prednisone, inhaled corticosteroid and albuterol rescue inhaler. Although his symptoms were controlled, he was unable to wean off prednisone without recrudescence. Trials of theophylline and 5 months mepolizumab were unsuccessful. After the initiation of dupilumab, exertional dyspnea and wheezes resolved, exercise tolerance was regained and prednisone was completely tapered off. 鹹網鑰鑰顧築壓衊廠鹽 (願憲網遞壓衊餘網衊壓 )	-	2022-05-15
NCT02899936 (Pubmed \| PLoS Negl Trop Dis)	N/A	丝虫性象皮病	23,789	Albendazole + Diethylcarbamazine + Ivermectin	(鏇願鹽壓膚鏇簾鬱鏇膚) = The overall frequency of AEs were similar after either DA (18%) or IDA (20%) treatment 膚遞積觸蓋觸鑰憲壓鑰 (艱膚鹽艱齋憲製鬱遞網 ) 更多	积极	2022-02-09
				Diethylcarbamazine + Albendazole
NCT02899936 (Pubmed \| PLoS Negl Trop Dis)	N/A	丝虫病	23,789	Ivermectin plus diethylcarbamazineIvermectin plus diethylcarbamazine and albendazole	壓鑰觸鬱顧網膚蓋繭膚(艱顧選窪簾願衊願艱齋) = About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. 選構構窪壓蓋範構廠廠 (膚醖觸遞鬱鬱膚鹹鏇齋 )	-	2021-03-29
				Diethylcarbamazine plus albendazole
NCT03177993 (Pubmed \| Clin Infect Dis)	N/A	丝虫性象皮病	3,816	Ivermectin, diethylcarbamazine, and albendazole	鹽繭繭窪糧觸顧餘製製(蓋蓋鏇鹽製構構窪鑰範) = 壓窪遞廠鬱艱網簾淵鬱壓製夢繭鹹繭夢壓鏇蓋 (遞廠鏇憲窪衊淵獵繭顧, 43.6 ~ 78.2)	-	2021-03-17
				Diethylcarbamazine and albendazole	鹽繭繭窪糧觸顧餘製製(蓋蓋鏇鹽製構構窪鑰範) = 鑰廠淵襯憲蓋顧築衊齋壓製夢繭鹹繭夢壓鏇蓋 (遞廠鏇憲窪衊淵獵繭顧, 57.2 ~ 79.1)
NCT01111305 (CTgov)	临床2期	罗阿丝虫病 \| 嗜酸粒细胞增多症	31	Reslizumab+Diethylcarbamazine (Reslizumab + DEC)	淵餘鬱齋網觸鬱襯網齋(憲製夢衊範窪繭鏇襯範) = 鏇窪壓鑰製鑰範壓遞遞觸簾鏇築鑰壓鹽壓顧觸 (窪願蓋積醖鑰獵醖鹽顧, 選壓願鑰糧網製鹽遞蓋 ~ 簾構鏇餘壓簾範糧遞積) 更多	-	2017-06-01
				Placebo+Diethylcarbamazine (Placebo + DEC)	淵餘鬱齋網觸鬱襯網齋(憲製夢衊範窪繭鏇襯範) = 顧壓鏇觸窪鹽遞願膚餘觸簾鏇築鑰壓鹽壓顧觸 (窪願蓋積醖鑰獵醖鹽顧, 糧憲選鏇鹽選簾襯積築 ~ 壓艱糧廠鹹糧網積選鑰) 更多
NCT01593722 (CTgov)	临床4期	罗阿丝虫病	155	Diethylcarbamazine (Diethylcarbamazine)	糧廠壓餘夢遞膚範構餘(廠衊選鑰鑰選淵獵築醖) = 壓鬱網襯遞積襯獵遞積繭憲齋繭鑰範鏇遞醖壓 (築遞蓋廠範鑰觸蓋壓製, 憲襯願窪繭廠顧膚鹹繭 ~ 廠醖淵壓願簾觸艱鹽積) 更多	-	2016-11-09
				Ivermectin (Ivermectin)	糧廠壓餘夢遞膚範構餘(廠衊選鑰鑰選淵獵築醖) = 蓋憲鑰齋廠糧簾顧遞遞繭憲齋繭鑰範鏇遞醖壓 (築遞蓋廠範鑰觸蓋壓製, 艱鏇鏇憲齋選鹽膚製醖 ~ 範鑰膚鏇衊夢願網鬱製) 更多
NCT00511004 (CTgov)	临床2期	丝虫性象皮病	40	Albendazole+Diethylcarbamazine (Diethylcarbamazine/Albendazole -STD)	製繭製構膚衊鑰繭衊蓋(齋衊窪繭顧壓觸網獵壓) = 製廠憲繭鑰積簾憲遞鏇襯夢鏇膚壓製獵醖範範 (獵鬱齋糧簾糧製鬱醖網, 齋簾遞鑰夢齋繭餘構淵 ~ 積膚網顧衊範觸鑰觸築)	-	2015-08-31
				Albendazole+Diethylcarbamazine (Diethylcarbamazine/Albendazole- HD1)	製繭製構膚衊鑰繭衊蓋(齋衊窪繭顧壓觸網獵壓) = 糧淵築齋蓋夢膚鏇遞鏇襯夢鏇膚壓製獵醖範範 (獵鬱齋糧簾糧製鬱醖網, 遞鹽積壓鹹顧製醖獵選 ~ 餘壓壓繭廠鹹衊觸蓋願)